Abstract:Technology in Cancer Research &Treatment, Volume 23, Issue , January-December 2024. ObjectiveThis study intends to examine the anticipatory power of clinical and radiological parameters in detecting clinically significant prostate cancer in patients demonstrating Prostate Imaging Reporting and Data System 3 lesions.MethodsThis was a retrospective study. The study included participation from 453 patients at the First Affiliated Hospital of Soochow University, sampled between September 2017 through August 2022. Each patient underwent a routine 12-core prostate biopsy followed by a 2 to 5 core fusion-targeted biopsy. We utilized both univariate and multivariate logistic regression analyses to identify the parameters that have a correlation with clinically significant prostate cancer. The predictive ability of these parameters was assessed using the receiver operating characteristic curve, leading to the creation of a nomogram.ResultsClinically significant prostate cancer was detected in 68 out of 453 patients with Prostate Imaging Reporting and Data System 3 lesions (15.01%). Among Prostate Imaging Reporting and Data System 3a and 3b patients, 4.78% (3.09% of the total) and 33.75% (11.92% of the total), respectively, had clinically significant prostate cancer. Systematic biopsy improved prostate cancer and clinically significant prostate cancer detection rates by 7.72% and 3.09%, respectively, compared to targeted biopsy. Without systematic biopsy, there would be an undetected rate of 15% for prostate cancer and 8.13% for clinically significant prostate cancer in Prostate Imaging Reporting and Data System 3b patients. Several clinical parameters, including age, prostate-specific antigen density, lesion volume, apparent diffusion coefficient, and digital rectal examination, were statistically significant in the logistic regression analysis for clinically significant prostate cancer. The individual diagnostic accuracies of these parameters for clinically significant prostate cancer were 0.648, 0.645, 0.75, 0.763, and 0.7, respectively, but their combined accuracy improved to 0.866. A well-fit nomogram based on the identified risk factors was constructed (χ2 = 10.254, P = .248).ConclusionThe combination of age, prostate-specific antigen density, lesion volume, apparent diffusion coefficient, and digital rectal examination presented a higher diagnostic value for clinically significant prostate cancer than any single parameter in patients with Prostate Imaging Reporting and Data System 3 lesions. Systematic biopsy proved crucial for biopsy-naive patients with Prostate Imaging Reporting and Data System 3 lesions and should not be omitted.

[Establishment of a Scoring System for Predicting the Positive Rate of Prostatic Biopsy for Prostate Cancer].

Multivariate study of factors affecting the results of prostate biopsy in PSA grey zone

Prostate Imaging-Reporting and Data System Version 2 in Combination with Clinical Parameters for Prostate Cancer Detection: a Single Center Experience

A multicenter retrospective study on evaluation of predicative factors for positive biopsy of prostate cancer in real-world setting

Establishing a Novel Prediction Model for Improving the Positive Rate of Prostate Biopsy

Factors Analysis about Predicting the Probability of Positive Initial Prostate Biopsy

Prevalence and Risk Factors of Prostate Cancer in Chinese Men with PSA 4–10 Ng/ml Who Underwent TRUS-Guided Prostate Biopsy: the Utilization of PAMD Score

AB189. Prevalence and risk factors of prostate cancer in Chinese men with PSA 4–10 ng/mL underwent TRUS-guided prostate biopsy: the utilization of PAMD score

Development and External Multicenter Validation of Chinese Prostate Cancer Consortium Prostate Cancer Risk Calculator for Initial Prostate Biopsy.

Clinical and Radiological Factors for Predicting Clinically Significant Prostate Cancer in Biopsy-Naive Patients With PI-RADS 3 Lesions

Transrectal Ultrasound Examination of Prostate Cancer Guided by Fusion Imaging of Multiparametric MRI and TRUS: Avoiding Unnecessary Mpmri-Guided Targeted Biopsy

Prediction of Prostate Cancer from Prostate Biopsy in Chinese Men Using a Genetic Score Derived from 24 Prostate Cancer Risk-Associated SNPs

Establishment of a nomogram for predicting positive repeat prostate biopsy in patients with total PSA 4 to 10 ng/ml

Predictive factors of prostate cancer at repeat biopsy in patients with elevated serum prostate-specific antigen

A Calculator Based on Prostate Imaging Reporting and Data System Version 2 (PI-RADS V2) is a Promising Prostate Cancer Predictor

Ultrasound‐based radiomics score for pre‐biopsy prediction of prostate cancer to reduce unnecessary biopsies

Performance of the Prostate Health Index in Predicting Prostate Biopsy Outcomes among Men with a Negative Digital Rectal Examination and Transrectal Ultrasonography.

Establishment of Two New Predictive Models for Prostate Cancer to Determine Whether to Require Prostate Biopsy when the PSA Level is in the Diagnostic Gray Zone (4–10 Ng Ml−1)

Preliminary Study on Ultrasound-Guided Prostate Biopsy Specimen Scores.

A Comprehensive Prostate Biopsy Standardization System According to Quantitative Multiparametric MRI and PSA Value: P.R.O.S.T Score

Multiparametric Transrectal Ultrasound for the Diagnosis of Peripheral Zone Prostate Cancer and Clinically Significant Prostate Cancer: Novel Scoring Systems